ENHANZE® Partnered Products
Janssen
DARZALEX FASPRO® (daratumumab and hyaluronidase human-fihj) (U.S./China)
DARZALEX® SC (daratumumab) (Outside U.S.)
DARZQURO® (daratumumab) (Japan)
Takeda
HYQVIA® [immune globulin infusion 10% (Human) with recombinant human hyaluronidase]
argenx
VYVGART® HYTRULO (efgartigimod alfa and hyaluronidase-qvfc) (U.S.)
VYVGART® (efgartigimod alfa) solution for injection (EU)
VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) combination subcutaneous injection (Japan)
Roche
PHESGO® (pertuzumab/trastuzumab/hyaluronidase-zzxf) (U.S.) (pertuzumab/trastuzumab) (EU)
TECENTRIQ HYBREZA™ (atezolizumab and hyaluronidase-tqjs) (U.S.)
TECENTRIQ® SC (atezolizumab) (Outside U.S.)
OCREVUS ZUNOVO™ (ocrelizumab & hyaluronidase-ocsq) (U.S.)
OCREVUS® SC (ocrelizumab) (EU)
RITUXAN HYCELA® (rituximab/hyaluronidase human) (U.S.)
MabThera® SC (rituximab) (Outside U.S.)
HERCEPTIN HYLECTA™ SC (trastuzumab and hyaluronidase-oysk) (U.S.)
Herceptin® SC (trastuzumab) (Outside U.S.)
ENHANZE® by the Numbers
Commercial
8 commercial partnered products with ENHANZE® licensing
800,000+ patients treated in 100+ global markets
10s of billions of dollars in cumulative partner product sales
Regulatory
20+ partner programs to FIH dosing
100% success record (8 for 8) of regulatory approvals
Technical
100% of 40+ monoclonal antibodies tested to date demonstrated short term compatibility
2,500+ subjects characterized for immunogenicity across 18+ studies
2 commercial-scale GMP sources for robust rHuPH20 supply